Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind dose-ranging study of PF-06480605 in moderate to severe ulcerative colitis
2019-002698-74Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing PF-06480605 dose-ranging with Placebo (2 arms). Primary endpoint: Clinical remission at Week 14 (Total Mayo Score). Started Jan 2020; status: completed.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-002698-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002698-74.